Marino Muxfeldt Bianchin

Dr. Marino Muxfeldt Bianchin


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2020 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
RBRosane Brondani
Rosane Brondani
AAAndrea Garcia de Almeida
Andrea Garcia de Almeida
PCPedro Abrahim Cherubini
Pedro Abrahim Cherubini
TSThaís Leite Secchi
Thaís Leite Secchi
MOMarina Amaral de Oliveira
Marina Amaral de Oliveira
MBMarino Muxfeldt Bianchin
Marino Muxfeldt Bianchin
The effects of thrombolysis in seizure and epilepsy after acute ischemic stroke have been poorly explored. In this study, we examine risk factors and consequences of intravenous rt-PA for treatment of acute ischemic stroke. In a retrospective cohort study we evaluate risk factors for seizure and epilepsy after stroke thrombolysis, as well as the impact of seizures and epilepsy in outcome of stroke patients. In our cohort, mean age of patients was 67.2 years old (SD = 13.1) and 79 of them (51.6%) were male and. Initial NIHSS mean score were 10.95 (SD = 6.25). Three months NIHSS mean score was 2.09 (SD = 3.55). Eighty seven (56.9%) patients were mRS of 0–1 after thrombolysis. Hemorrhagic transformation was observed in 22 (14.4%) patients. Twenty-one (13.7%) patients had seizures and 15 (9.8%) patients developed epilepsy after thrombolysis. Seizures were independently associated with hemorrhagic transformation (OR = 3.26; 95% CI = 1.08–9.78; p = 0.035) and with mRS ≥ 2 at 3 months after stroke (OR = 3.51; 95% CI = 1.20–10.32; p = 0.022). Hemorrhagic transformation (OR = 3.55; 95% CI = 1.11–11.34; p = 0.033) and mRS ≥ 2 at 3 months (OR = 5.82; 95% CI = 1.45–23.42; p = 0.013) were variables independently associated with post-stroke epilepsy. In our study, independent risks factors for poor outcome in stroke thrombolysis were age (OR = 1.03; 95% CI = 1.01–1.06; p = 0.011), higher NIHSS (OR = 1.08; 95% CI = 1.03–1.14; p = 0.001), hemorrhagic transformation (OR = 2.33; 95% CI = 1.11–4.76; p = 0.024), seizures (OR = 3.07; 95% CI = 1.22–7.75; p = 0.018) and large cortical area (ASPECTS ≤ 7) (OR = 2.04; 95% CI = 1.04–3.84; p = 0.036). Concluding, in this retrospective cohort study, the neurological impairment after thrombolysis (but not before) and hemorrhagic transformation remained independent risk factors for seizures or post-stroke epilepsy after thrombolysis. Moreover, we observed that seizures emerged as an independent risk factor for poor outcome after thrombolysis therapy in stroke patients (OR = 3.07; 95% CI = 1.22–7.75; p = 0.018).

30 March 2017 in Cerebrovascular Diseases Extra
Verified
Journal Article
Open access
PDF file
RBRosane Brondani
Rosane Brondani
AAAndrea Garcia de Almeida
Andrea Garcia de Almeida
PCPedro Abrahim Cherubini
Pedro Abrahim Cherubini
SMSuelen Mandelli Mota
Suelen Mandelli Mota
LALuiz Carlos de Alencastro
Luiz Carlos de Alencastro
MBMarino Muxfeldt Bianchin
Marino Muxfeldt Bianchin
Background: Decompressive hemicraniectomy (DHC) is a life-saving procedure for treatment of large malignant middle cerebral artery (MCA) strokes. Post-stroke epilepsy is an additional burden for these patients, but its incidence and the risk factors for its development have been poorly investigated. Objective: To report the prevalence and risk factors for post-stroke seizures and post-stroke epilepsy after DHC for treatment of large malignant MCA strokes in a cohort of 36 patients. Methods: In a retrospective cohort study of 36 patients we report the timing and incidence of post-stroke epilepsy. We analyzed if age, sex, vascular risk factors, side of ischemia, reperfusion therapy, stroke etiology, extension of stroke, hemorrhagic transformation, ECASS scores, National Institutes of Health Stroke Scale (NIHSS) scores, or modified Rankin scores were risk factors for seizure or epilepsy after DHC for treatment of large MCA strokes. Results: The mean patient follow-up time was 1,086 days (SD = 1,172). Out of 36 patients, 9 (25.0%) died before being discharged. After 1 year, a total of 11 patients (30.6%) had died, but 22 (61.1%) of them had a modified Rankin score ≤4. Thirteen patients (36.1%) developed seizures within the first week after stroke. Seizures occurred in 22 (61.1%) of 36 patients (95% CI = 45.17–77.03%). Out of 34 patients who survived the acute period, 19 (55.9%) developed epilepsy after MCA infarcts and DHC (95% CI = 39.21–72.59%). In this study, no significant differences were observed between the patients who developed seizures or epilepsy and those who remained free of seizures or epilepsy regarding age, sex, side of stroke, presence of the clinical risk factors studied, hemorrhagic transformation, time of craniectomy, and Rankin score after 1 year of stroke. Conclusion: The incidence of seizures and epilepsy after malignant MCA infarcts submitted to DHC might be very high. Seizure might occur precociously in patients who are not submitted to anticonvulsant prophylaxis. The large stroke volume and the large cortical ischemic area seem to be the main risk factors for seizure or epilepsy development in this subtype of stroke.

17 May 2019 in Neurocritical Care
Verified
Journal Article
Closed access
PDF file
CRCarla B. Rynkowski
Carla B. Rynkowski
AMAirton Leonardo de Oliveira Manoel
Airton Leonardo de Oliveira Manoel
MRMarcelo Martins dos Reis
Marcelo Martins dos Reis
CPCorina Puppo
Corina Puppo
PWPaulo Valdeci Worm
Paulo Valdeci Worm
MBMarino Muxfeldt Bianchin
Marino Muxfeldt Bianchin

1 November 2017 in Epilepsy & Behavior
Verified
Journal Article
Closed access
MBMarino Muxfeldt Bianchin
Marino Muxfeldt Bianchin
TVTonicarlo Rodrigues Velasco
Tonicarlo Rodrigues Velasco
LWLauro Wichert-Ana
Lauro Wichert-Ana
ASAntonio Carlos dos Santos
Antonio Carlos dos Santos
ASAmérico Ceiki Sakamoto
Américo Ceiki Sakamoto

1 November 2017 in Epilepsy Research
Verified
Journal Article
Closed access
CTCarolina Machado Torres
Carolina Machado Torres
MSMarina Siebert
Marina Siebert
HBHugo Bock
Hugo Bock
SMSuelen Mandelli Mota
Suelen Mandelli Mota
BKBárbara Reis Krammer
Bárbara Reis Krammer
MBMarino Muxfeldt Bianchin
Marino Muxfeldt Bianchin

8 December 2021 in Frontiers in Integrative Neuroscience
Verified
Journal Article
Open access
SMSuelen Mandelli Mota
Suelen Mandelli Mota
LCLuiza Amaral de Castro
Luiza Amaral de Castro
PRPatrícia Gabriela Riedel
Patrícia Gabriela Riedel
CTCarolina Machado Torres
Carolina Machado Torres
JBJosé Augusto Bragatti
José Augusto Bragatti
MBMarino Muxfeldt Bianchin
Marino Muxfeldt Bianchin
We conducted a double-blind randomized clinical trial in order to examine the effects and the safety of home-based transcranial direct current stimulation (tDCS) on depressive and anxious symptoms of patients with temporal lobe epilepsy (TLE). We evaluated 26 adults with TLE and depressive symptoms randomized into two different groups: active tDCS (tDCSa) and Sham (tDCSs). The patients were first submitted to 20 sessions of tDCS for 20 min daily, 5 days a week for 4 weeks and then received a maintenance tDCS application in the research laboratory once a week for 3 weeks. The intensity of the current was 2 mA, applied bilaterally over the dorsolateral prefrontal cortex, with the anode positioned on the left side and the cathode on the right side. Participants were evaluated on days 1, 15, 30, and 60 of the study using the Beck Depression Inventory II (BDI). A follow-up evaluation was performed 1 year after the end of treatment. They were also evaluated for quality of life and for anxious symptoms as secondary outcomes. The groups did not differ in clinical, socioeconomic or psychometric characteristics at the initial assessment. There was no statistically significant difference between groups regarding reported adverse effects, seizure frequency or dropouts. On average, between the 1st and 60th day, the BDI score decreased by 43.93% in the active group and by 44.67% in the Sham group (ΔBDIfinal – initial = −12.54 vs. −12.20, p = 0.68). The similar improvement in depressive symptoms observed in both groups was attributed to placebo effect and interaction between participants and research group and not to tDCS intervention per se. In our study, tDCS was safe and well tolerated, but it was not effective in reducing depressive or anxiety symptoms in patients with temporal lobe epilepsy.Clinical Trial Registration: [ClinicalTrials.gov], identifier [NCT03871842].